Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice

Journal of Neuroscience Research

Volumn 67, Issue 3, 2002, Pages 372-378

  MacGibbon, G A ^a   Hamilton, L C ^a   Crocker, S F ^a   Costain, W J ^a   Murphy, K M ^a   Robertson, H A ^a   Denovan Wright, E M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

c Fos; Gene expression; Krox 24; Neurodegeneration; Striatum

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HUNTINGTIN; KAINIC ACID; METHAMPHETAMINE; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; IMMEDIATE EARLY GENE; IN SITU HYBRIDIZATION; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTI-DYSKINESIA AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS CALLOSUM; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOPAMINE ANTAGONISTS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION; GENES, IMMEDIATE-EARLY; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; HUNTINGTON DISEASE; IMMEDIATE-EARLY PROTEINS; METHAMPHETAMINE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; QUINOLINIC ACID; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 0036469255     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10100     Document Type: Article

References (34)

1. N-methyl-D-aspartate receptor activation in the neostriatum increases c-Fos and Fos-related antigens selectively in medium-sized neurons
2. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
3. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
4. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
5. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
6. Transcriptional dysregulation in Huntington's disease
7. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington's disease gene
8. Lesion of striatal neurones with kainic acid provides a model for Huntington chorea
9. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress
10. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
11. Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat
12. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
13. Excitotoxic injury of the neostriatum: A model for Huntington's disease
14. Presence of c-fos-like immunoreactivity in the adult rat brain
15. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons
16. DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission
17. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
18. Inducible and constitutive transcription factors in the mammalian nervous system: Control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins
19. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity
20. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis
21. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
22. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease
23. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation
24. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
25. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
26. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: Comparison with acute haloperidol effects
27. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity
28. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
29. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain
30. Excitotoxic models for neurodegenerative disorders
31. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons
32. Methamphetamine-induced nuclear c-Fos in rat brain regions
33. Huntington's disease
34. Immediate early gene activation during the initial phases of the excitotoxic cascade